COVID-19 vaccine trial data for kids coming by end of year: Pfizer

Click to play video: 'Pfizer, Moderna says studies underway on children under 12; Anand says enough supply once approved'
Pfizer, Moderna says studies underway on children under 12; Anand says enough supply once approved
WATCH: Pfizer and Moderna officials said that studies were underway on COVID-19 vaccines for children under 12 – Jul 27, 2021

Pfizer intends to submit data to Health Canada on trials of its COVID-19 vaccine in children under 12 by the end of the year, the company told Global News.

In a statement, Pfizer said that it had completed its Phase 1 trial of the vaccine in children, which was designed to determine the optimal dose for kids of different age groups.

Phase 2 and 3 trials are ongoing, the company said, “to further evaluate the safety, tolerability, and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine in children 5-11, and in children 6 months-5 years.”

Read more: Provinces divided on making use of COVID-19 vaccine passports. Here’s why

Read next: Former Alberta CMOH Deena Hinshaw appointed to public health leadership role in B.C.

“If safety and immunogenicity is confirmed, we plan on filing the data to Health Canada before the end of the year to support a potential authorization in children 5 to 11 years of age, and soon after for 6 months to 5 years,” wrote the company.

Story continues below advertisement

This data needs to be reviewed by Health Canada to determine whether the government will authorize the use of the Pfizer-BioNTech vaccine in children under 12. Health Canada approved use of the vaccine in children aged 12-16 in May 2021.

Read more: How vulnerable will children be in Canada’s fourth wave of COVID-19?

Read next: Ottawa set to introduce new assisted dying bill for mental disorders

Moderna, which makes a COVID-19 vaccine approved for use in people older than 16, said only that its study of the vaccine in the pediatric population is “ongoing” and would not provide details on a timeline.

AstraZeneca said that its partner Oxford University was currently conducting trials on the pediatric population for its vaccine.

“The trial continues with no safety concerns and details of immune responses will be provided when available,” the company said in a statement.

— With files from Rachel Gilmore, Global News

Sponsored content